MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Parkinsonism"

  • 2019 International Congress

    The Relationship of Neuropsychiatric Symptoms and Cognitive Impairment in Parkinson’s Disease

    B. Bernard, G. Stebbins, A. Negron, D. Merkitch, J. Goldman (Chicago, IL, USA)

    Objective: To assess the relationship between individual items from the Neuropsychiatric Inventory and five cognitive domains in patients with Parkinson's disease (PD) and normal cognitive…
  • 2019 International Congress

    Relationships of gender, care models, and neuropsychiatric symptoms in Parkinson’s disease

    J. Goldman, S. Wu, C. Martinez-Rubio, V. Todaro (New York, NY, USA)

    Objective: To examine relationships among gender, care models, and presence and management of neuropsychiatric symptoms of Parkinson’s disease (PD). Background: Neuropsychiatric symptoms such as depression…
  • 2019 International Congress

    Evaluating Volume Changes in the Substantia Nigra Pars Compacta (SNc) in Parkinson’s Disease (PD) in a Study-Specific Magnetic Resonance Imaging (MRI) Template

    E. Biondetti, R. Gaurav, L. Yahia-Cherif, G. Mangone, N. Pyatigorskaya, R. Valabregue, C. Ewenczyk, M. Hutchison, JC. Corvol, MJ. Vidailhet, S. Lehéricy (Paris, France)

    Objective: To characterize the topography of SNc involvement in PD patients using neuromelanin (NM)-sensitive MRI (NM-MRI). Background: PD is characterized by the progressive loss of…
  • 2019 International Congress

    “Brain-first” vs. “body-first” Parkinson’s disease is determined by RBD-status – a multi-modality imaging study

    J. Horsager, K. Knudsen, K. Andersen, C. Skjærbæk, T. Fedorova, J. Geday, J. Kraft, E. Bech, E. Danielsen, M. Møller, N. Pavese, D. Brooks, P. Borghammer (Aarhus N, Denmark)

    Objective: In a multi-modality imaging study, we test the hypothesis that Parkinson’s disease (PD) can be divided into two strikingly distinct phenotypes: (1) PD patients,…
  • 2019 International Congress

    Functional Biomarkers of Parkinson’s Disease: Changes in Brain-Wide Network Connectivity in Default Mode and Fronto-Parietal Control Networks

    P. Macdonald, N. Hiebert, L. Naci, A. Owen (Dublin, Ireland)

    Objective: Parkinson’s disease (PD) is a neurological disorder with no reliable biomarkers. We aimed to investigate naturalistic paradigms as functional biomarkers that distinguish between PD…
  • 2019 International Congress

    Genotype influences circuit compensation in Parkinson’s disease

    K. Schindlbeck, A. Vo, N. Nguyen, C. Tang, M. Niethammer, V. Dhawan, V. Brandt, R. Saunders-Pullman, S. Bressman, D. Eidelberg (Manhasset, NY, USA)

    Objective: This study investigates differences in brain network organization in patients with Parkinson’s disease (PD) with genetic risk factors relative to sporadic PD patients and…
  • 2019 International Congress

    The efficiency of group cognitive rehabilitation to patients with Parkinson’s disease in comparison to relaxation therapy: pilot data

    V. Plzáková, D. Enström, T. Nikolai (Prague, Czech Republic)

    Objective: The aim of this study was to compare the efficiency of group cognitive rehabilitation to patients with Parkinson´s disease (PD) in comparison to group…
  • 2019 International Congress

    Validation of the ‘ecological momentary assessment’ (EMA) method as a tool for daily life monitoring in patients with Parkinson’s disease

    J. Habets, M. Heijmans, C. Herff, C. Simons, A. Leentjens, Y. Temel, M. Kuijf, P. Kubben (Maastricht, Netherlands)

    Objective: To validate the ‘ecological momentary assessment’ (EMA) method, also known as the ‘experience sampling method’ (ESM), as an instrument to monitor symptoms of PD.…
  • 2019 International Congress

    Safinamide improves motor symptoms severity and daily living in Parkinson’s Disease (PD) patients

    C. Cattaneo, E. Bonizzoni, C. Keywood (Milan, Italy)

    Objective: To evaluate the clinical effects of safinamide, administered as add-on therapy to levodopa in fluctuating PD patients, on symptoms severity and daily living. Background:…
  • 2019 International Congress

    Design, characterization and In vivo evaluation of intranasal delivery of levodopa loaded microspere for Parkinsonism

    S. Jain, A. Jain, SB. Bhargav (Sagar, India)

    Objective: Levodopa is the drug of choice in the treatment of Parkinson's disease but it exhibits low oral bioavailability and very low brain uptake. The…
  • « Previous Page
  • 1
  • …
  • 149
  • 150
  • 151
  • 152
  • 153
  • …
  • 405
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley